Q4 2024 Holdings
Filed 2025-02-14 | 39 holdings | $7.1B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $973.9M | 2,760,300 | 13.8% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $761.7M | 1,238,467 | 10.8% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $702.5M | 5,103,055 | 9.9% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $626.1M | 2,029,000 | 8.9% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $411.8M | 2,628,822 | 5.8% |
| Apellis Pharmaceuticals Inc.(APLS) | Common | 03753U106 | $390.0M | 12,222,222 | 5.5% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $310.7M | 2,555,555 | 4.4% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $254.7M | 3,050,000 | 3.6% |
| Vera Therapeutics Inc(VERA) | Common | 92337R101 | $237.2M | 5,610,000 | 3.4% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $222.1M | 5,666,666 | 3.1% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $218.3M | 23,175,000 | 3.1% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $218.1M | 7,500,000 | 3.1% |
| Arrowhead Pharmaceuticals Inc.(ARWR) | Common | 04280A100 | $208.9M | 11,111,111 | 3.0% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $207.2M | 5,150,000 | 2.9% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $150.0M | 2,770,100 | 2.1% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $113.5M | 2,525,000 | 1.6% |
| Blueprint Medicines Corp(2L9) | Common | 09627Y109 | $103.4M | 1,185,000 | 1.5% |
| Vaxcyte Inc(PCVX) | Common | 92243G108 | $96.2M | 1,175,000 | 1.4% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $96.1M | 1,462,500 | 1.4% |
| Merus N V | Common | N5749R100 | $89.4M | 2,125,000 | 1.3% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $89.2M | 11,865,000 | 1.3% |
| Alkermes PLC(ALKS) | Common | G01767105 | $70.5M | 2,450,000 | 1.0% |
| Ocular Therapeutix Inc(OCUL) | Common | 67576A100 | $68.8M | 8,060,000 | 1.0% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $56.3M | 8,750,000 | 0.8% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $45.1M | 2,222,222 | 0.6% |
| Uniqure NV(QURE) | Common | N90064101 | $38.4M | 2,175,000 | 0.5% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $34.9M | 830,000 | 0.5% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $34.6M | 19,999,999 | 0.5% |
| 89Bio Inc(ETNBGBP) | Common | 282559103 | $32.1M | 4,100,000 | 0.5% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $30.2M | 4,345,000 | 0.4% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $30.1M | 2,275,000 | 0.4% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $25.9M | 3,500,000 | 0.4% |
| Septerna Inc(SEPN) | Common | 81734D104 | $25.4M | 1,110,000 | 0.4% |
| Autolus Therapeutics PLC(AUTL) | Sponsored ADR | 05280R100 | $23.3M | 9,910,642 | 0.3% |
| CG Oncology Inc(CGON) | Common | 156944100 | $20.1M | 700,000 | 0.3% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $19.6M | 2,250,000 | 0.3% |
| Rocket Pharmaceuticals Inc(RCKT) | Common | 77313F106 | $15.1M | 1,200,000 | 0.2% |
| Olema Pharmaceuticals Inc(OLMA) | Common | 68062P106 | $9.6M | 1,651,982 | 0.1% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $9.0M | 2,849,402 | 0.1% |